Prof. Marco Perez (Stanford University, USA) presented new findings from this study, showing that the pulse sensor paired with a mobile app identified important arrhythmias apart from AF with a high positive predictive value [1]. The study had two co-primary endpoints: (1) AF >30 seconds as validated by ECG patch monitoring, and (2) simultaneous ECG patch-validated AF and irregular patient tachogram. Key secondary outcomes were simultaneous AF on ECG patch monitoring while the pulse notification algorithm detected an irregular pulse, and post-study healthcare provider intervention within 3 months after an irregular pulse notification.
The study, published in the New England Journal of Medicine [2], showed that an irregular pulse was detected in 0.52% of the 419,297 participants between November 2017 and February 2019. Participants were required to own an Apple Watch and iPhone and to install the study app that used an irregular pulse notification algorithm. If the pulse algorithm registered an irregular tachogram, sampling frequency was increased. If 5 out of 6 tachograms within a subsequent 48-hour period were irregular, a notification was sent to the participant, who would be recommended to contact a study physician by video consultation. As a result, 658 participants (0.16% of total) received an ECG patch by mail to wear for up to 7 days, of which 450 were returned for analysis (23% women; 40% >65 years).
Of the 450 participants who returned ECG patches, 18 patients had heart rates >200 bpm, 1 had a pulse pause of >6 seconds, and 1 had ventricular tachycardia for >6 seconds. In this study, 153 (34%) of the returned ECG patches confirmed AF. Among participants who were notified of an irregular pulse, the positive predictive value was 0.84 (95% CI 0.76-0.92) for observing AF on the ECG simultaneously with a subsequent irregular pulse notification. Among 297 participants who were shown to not have AF, 74 (25%) did have premature atrial contraction burden between 1-15%, and 4 (1.3%) participants had a burden of >15%. High-grade atrioventricular block episodes were identified in 3 patients that were linked to transient sinus slowing that lasted <4 seconds. In addition, 2 individuals were identified with premature ventricular contractions of >15%, and 11 participants (3.7%) had an episode of ventricular tachycardia for >8 heartbeats. The investigators concluded that the wearable technology had adequate sensitivity to detect AF as well as rarer arrhythmias in the general population and that this approach could potentially identify asymptomatic individuals at significant risk and direct them to specialised care.
- Perez MV, et al. Apple Watch App Identifies Clinically Important Arrhythmias Other Than Atrial Fibrillation: Results From the Apple Heart Study. FS.AOS.04, AHA Scientific Sessions 2019, 14-18 November, Philadelphia, USA.
- Perez MV, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med 2019;381:1909-1917.
Posted on
Previous Article
« Balloon-expandable better than self-expanding transcatheter heart valves Next Article
FUEL trial: Udenafil improves some exercise measurements in Fontan »
« Balloon-expandable better than self-expanding transcatheter heart valves Next Article
FUEL trial: Udenafil improves some exercise measurements in Fontan »
Table of Contents: AHA 2019
Featured articles
New Approaches to CVD Risk Reduction
Phase 3 BETonMACE trial did not meet its primary endpoint
Inclisiran safely halves LDL-Cholesterol
Colchicine prevents cardiovascular events
Interventional Management for Acute Coronary Syndrome
Drop aspirin after 3 months in non-STEMI ACS patients on dual antiplatelet therapy
Immediate coronary angiography after cardiac arrest does not improve survival
Complete revascularisation for obstructive non-culprit lesions with vulnerable plaque
Colchicine: no difference in peri-procedural cardiovascular events 30 days post-PCI
Intra-aortic balloon pump better than Impella: new observational data
Results for the Ischemia Trials: To Intervene or Not to Intervene
ISCHEMIA trial: Invasive treatment only better for angina burden
Controversies in Contemporary Management of Aortic Stenosis
Full GALILEO results: Why did rivaroxaban fail after TAVR?
Balloon-expandable better than self-expanding transcatheter heart valves
RECOVERY: Benefit of early surgery in asymptomatic severe aortic stenosis
Guidelines: Updates and Controversies
New guidelines on the prevention of cardiovascular conditions
Trials in Electrophysiology and Left Ventricular Function
RENAL-AF trial: Apixaban similar to warfarin
Apple Heart Study: Not just for atrial fibrillation
Early apixaban safe as secondary prevention of stroke from AF
Carvedilol does not improve exercise performance in Fontan patients
New Frontiers in Lipid Therapy
Icosapent ethyl plus statins reduces total plaque volume
ORION-9: Inclisiran RNAi halves LDL in familial hypercholesterolaemia patients
New RNAi therapies to reduce triglycerides: 2 studies show favourable results
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
Challenges in Heart Failure Management
FUEL trial: Udenafil improves some exercise measurements in Fontan
DAPA-HF: Dapagliflozin also good for heart failure patients without diabetes, of any age, or any health status
PARAGON-HF: Benefits for women and lower ejection fraction
Related Articles
February 26, 2020
Editor Biography
February 26, 2020
Targeting LDL-C <70 mg/dL is better than 100 mg/dL after stroke
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com